Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66581-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- STT3A antibody
- Antibody type
- Monoclonal
- Description
- STT3A antibody (Cat. #66581-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1E2B12
- Vial size
- 20ul, 150ul
Submitted references Oligosaccharyltransferase (OST) complex inhibition effectively treats rodent and human prions.
Integrative single-cell and bulk RNA-seq analysis identifies glycosyltransferases-related signature in triple negative breast cancer.
STT3A is essential for Wnt signaling and represents a target for cancers driven by RNF43 deficiency.
N-glycosylation Modification of CTSD Affects Liver Metastases in Colorectal Cancer.
Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor's Efficacy for Breast Cancer.
Targeting STT3A produces an anti-tumor effect in lung adenocarcinoma by blocking the MAPK and PI3K/AKT signaling pathway.
Beauchemin KS, Kun J, Groveman B, Williams K, Salerno F, Francomacaro LM, Robison P, Haigh CL, Supattapone S
PLoS pathogens 2026 Jan;22(1):e1013867
PLoS pathogens 2026 Jan;22(1):e1013867
Integrative single-cell and bulk RNA-seq analysis identifies glycosyltransferases-related signature in triple negative breast cancer.
Hu J, Yuan N, Huang Z, Liu Y, Tu B, Yu X, Hui T, Zuo G
Functional & integrative genomics 2025 Nov 8;25(1):233
Functional & integrative genomics 2025 Nov 8;25(1):233
STT3A is essential for Wnt signaling and represents a target for cancers driven by RNF43 deficiency.
He Z, Chen S, Suo J, Xia K, Liu M, Ma J, Chu Y, Wang C, Xie Y, Jiang W, Du H, Chen S, Zhou Z, Li M, Wei Q, Zhao Y, Chen J, Li L, Zeng Y, Zou W, Lin M, Jiang H
Cell chemical biology 2025 Nov 20;32(11):1321-1335.e6
Cell chemical biology 2025 Nov 20;32(11):1321-1335.e6
N-glycosylation Modification of CTSD Affects Liver Metastases in Colorectal Cancer.
Xiong N, Du Y, Huang C, Yan Q, Zhao L, Yang C, Sun Q, Gao Z, Wang C, Zhan J, Zhang H, Wang S, Ye Y, Li Y, Shen Z
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Feb;12(7):e2411740
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Feb;12(7):e2411740
Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D, Xie J, Sun F, Xu R, Liu W, Xu J, Huang X, Zhang G
Cancer letters 2024 May 1;589:216819
Cancer letters 2024 May 1;589:216819
Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor's Efficacy for Breast Cancer.
Lv W, Yu H, Han M, Tan Y, Wu M, Zhang J, Wu Y, Zhang Q
Frontiers in immunology 2022;13:830158
Frontiers in immunology 2022;13:830158
Targeting STT3A produces an anti-tumor effect in lung adenocarcinoma by blocking the MAPK and PI3K/AKT signaling pathway.
Cheng J, Xia L, Hao X, Gan F, Bai Y, Zhang C, Mao Y, Zhu Y, Pu Q, Park DW, Tavolari S, Mei J, Chen Y, Deng S, Liu L
Translational lung cancer research 2022 Jun;11(6):1089-1107
Translational lung cancer research 2022 Jun;11(6):1089-1107
No comments: Submit comment
No validations: Submit validation data